The spokesman for the parliament's health committee Salman Es’haghi confirmed that the deaths of at least 70 dialysis patients were due to aluminum-contaminated medication.
In June, Iran International reported that Samen Pharmaceutical Company, a subsidiary of the influential Astan Quds Razavi, is the sole producer of the medication.
Without revealing the manufacturer's identity, Es’haghi added that production of the medication has not been halted and while suggesting that a legal case was filed at the time, said the judiciary has yet to initiate serious legal action for accountability.
The Ministry of Health said Monday that the deaths were cases from the previous year, and that there is no cause for concern today.
The contamination surfaced in early 2024, initially with reports of fatalities among dialysis patients in Mashhad and Isfahan.
Early estimates cited 10 to 12 deaths, but as investigations progressed, the toll quickly climbed to 50, eventually reaching 70 confirmed deaths.
Symptoms included brain dysfunction, seizures, infections, and coma - all consistent with aluminum toxicity.
Es’haghi said that the initial assumption was low-quality production, but later findings suggested contamination with aluminum, leading to severe complications.